Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
Roche keeps Venclexta train rolling with new leukaemia filing
Roche keeps Venclexta train rolling with new leukaemia filing. The drug could treat AML patients who are ineligible for chemotherapy. ... up on what is seen with standard induction chemotherapy – and with responses typically lasting at least nine months
Latest news
-
Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
About 4% to 5% of metastatic colorectal cancer patients have those mutations, and make them less likely to benefit from conventional chemotherapy.
-
Pivotal data sets up Tecentriq filing in small cell lung cancer
Tecentriq (atezolizumab) as a front-line therapy in combination with chemotherapy for ES-SCLC. ... The company is currently running a phase III trial ( KeyNote-604) of its PD-1 inhibitor as a first-line therapy for ES-SCLC in combination with chemotherapy
-
Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach
NICE said Opdivo could not be used in patients with advanced, unresectable or metastatic urothelial cancer after platinum-containing chemotherapy because of lack of clinical and cost effectiveness data compared to
-
Sanofi’s rare blood disorder drug Cablivi set for European approval
If fully approved by the European Commission – which almost invariably follows CHMP backing – the drug will become the first chemotherapy option specifically for therapy-related AML or AML with myelodysplasia-related
-
Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more
2 months compared to 4.7 months for patients treated with salvage chemotherapy.
More from news
Approximately 6 fully matching, plus 807 partially matching documents found.
Latest Intelligence
-
The threat of antimicrobial resistance
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
-
Taking a lean and careful approach
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
-
Reactivating drug research programmes
In the case of cancer treatment, such drugs could also help to limit the use of traditional chemotherapy, which can be costly and have undesirable side effects.
-
Deal Watch February 2017
As an ADC IMMU-132 contains SN-38, which is the active metabolite of the chemotherapy agent irinotecan, conjugated to an anti-TROP-2 antibody.
-
Deal Watch November 2016
were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
AP Pharma appoints Dendreon’ s Jesse Hollingsworth to lead sales. Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Bayer’ s former oncology head Robert Rosen joins AP Pharma. Will lead launch of drug to prevent chemotherapy-induced nausea. ... In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
Virtual reality—a change for the better in medical education
Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum. ... 2012; 181:53– 7. Schneider SM, Kisby CK, Flint EP. Effect of virtual reality on time perception in patients receiving chemotherapy.
-
Forecasting in Dynamic Oncology Markets
future. Industry commentators believe immuno-oncology to be the third major breakthrough in cancer treatment, following the early days of chemotherapy and the targeted treatments that followed on from them. ... Only by combining with traditional
-
How pembrolizumab will change the management of advanced lung cancer
Summary/transcript. The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1
-
Products as portfolios: positioning immuno-oncology products
These changes, in turn, are having a fundamental impact on approaches to treatment and standards of care in the same way that surgery, radiotherapy, and chemotherapy have done in the past.
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
Featured jobs
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
PMHub
CACTUS
Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
